drugset
drugset / Trial / NCT06026878

GNT Induction Treatment in Locally Advanced NPC

NCT06026878 ↗

Phase 3 Recruiting 228 enrolled Air Force Military Medical University, China
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to compare overall response rate between gemcitabine, nimotuzumab and toripalimab as induction treatment and gemcitabine combined with cisplatine in paitents with locally advanced nasopharyngeal carcinoma. It aims to answer whether gemcitabine, nimotuzumab and toripalimab as induction treatment show non-inferiority compared to GP induction chemotherapy. Participants will be randomly divided into two induction treatment groups.

Timeline

Start
2023-09-01
Primary completion
2025-09-30
Completion
2027-09-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cisplatin Other / unclassified 80 mg/m2 Intravenous
Comparator Gemcitabine Small molecule 1 g Intravenous
Subject Nimotuzumab Monoclonal antibody 400 mg —
Subject Toripalimab Monoclonal antibody 240 mg —

Indications

nasopharyngeal carcinoma